End Stage Renal Disease on Dialysis
Nephrology
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Boehringer IngelheimINGELHEIM, Germany
1 program1
Empagliflozin 25 mg vs PlaceboPhase 41 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Boehringer IngelheimEmpagliflozin 25 mg vs Placebo
Outset MedicalDialysate Flow Rate
Clinical Trials (2)
Total enrollment: 71 patients across 2 trials
Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
Start: Mar 2023Est. completion: Jun 202630 patients
Phase 4Recruiting
The Study of Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300
Start: Sep 2019Est. completion: Jan 202041 patients
N/ACompleted
Related Jobs in Nephrology
Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery
AstraZeneca
Sweden - Gothenburg
1w ago
Associate Director – Nephrology Market Access Strategy
Biogen
Cambridge, MA
1w ago
$164K - $226K/yr
Director, Strategy & Operations-Nephrology Franchise
Biogen
Cambridge, MA
1w ago
$195K - $269K/yr
Medical Science Liaison, CardioRenal - Portland, OR
AstraZeneca
Portland - OR, US
1w ago
Vice President, Head of Renal Sales
Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr
Specialty Account Manager, Nephrology- South Houston, Texas
Amgen
Texas - Houston, US
1w ago
$155K - $184K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 71 patients
2 companies competing in this space